Nilesh Chande
YOU?
Author Swipe
View article: <scp>IL23</scp> Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease
<span>IL23</span> Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease Open
Background Paradoxical psoriasis (PP) is an adverse drug reaction associated with anti‐tumour necrosis factor (TNF)‐α therapy leading to disfiguring skin lesions that may impact an individual's quality of life and affect their inflammatory…
View article: Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments
Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments Open
Background A temporal relationship between vedolizumab and new‐onset spondyloarthritis (SpA) has been suggested. Aims We evaluated the relationship between vedolizumab initiation and development of new‐onset SpA in patients with inflammato…
View article: Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada
Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada Open
Background Cannabis is used by patients with Crohn’s disease (CD) and ulcerative colitis (UC) as an alternative to, or in combination with, conventional therapies to treat symptoms such as abdominal pain, poor sleep, and reduced appetite. …
View article: Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease
Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease Open
Background The extent of disease severity remains unclear among CYP2C19 rapid and ultra-rapid metabolizers with refractory symptoms of gastroesophageal reflux disease (GERD) on chronic proton-pump inhibitors (PPIs). Aims To determine the i…
View article: P696 Initiation of Vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A Prospective Study Including Rheumatological and Blinded Imaging Assessments
P696 Initiation of Vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A Prospective Study Including Rheumatological and Blinded Imaging Assessments Open
Background Prior case series indicated a temporal relationship between use of vedolizumab and new-onset spondyloarthritis. Methods We aimed to evaluate the relationship between initiation of vedolizumab and development of new-onset spondyl…
View article: A86 CANNABIS USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS HIGHER FOLLOWING LEGALIZATION OF CANNABIS IN CANADA AND IS ASSOCIATED WITH LOWER QUALITY OF LIFE
A86 CANNABIS USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS HIGHER FOLLOWING LEGALIZATION OF CANNABIS IN CANADA AND IS ASSOCIATED WITH LOWER QUALITY OF LIFE Open
Background Patients with inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), often experience fluctuating and unpredictable symptoms. Most individuals require chronic therapy with immunomodulators …
View article: A142 IMPACT OF <i>HLADQA1*05G&gt;A</i> GENETIC-SCREENING FOR OPTIMAL ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE: A PRELIMINARY REPORT
A142 IMPACT OF <i>HLADQA1*05G>A</i> GENETIC-SCREENING FOR OPTIMAL ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASE: A PRELIMINARY REPORT Open
Background Genetic variation in the human leukocyte antigen ( HLA) gene is strongly associated with the formation of anti-drug antibodies to tumor necrosis factor-alpha antagonists (anti-TNF) in inflammatory bowel disease (IBD). It is also…
View article: A166 CANNABIS USE IN CANADIAN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE FOLLOWING LEGALIZATION OF CANNABIS
A166 CANNABIS USE IN CANADIAN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE FOLLOWING LEGALIZATION OF CANNABIS Open
Background Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by remitting and relapsing symptoms of abdominal pain, diarrhea, nausea, fatigue, and poor sleep. Most patients with…
View article: Ozanimod for the Treatment of Ulcerative Colitis
Ozanimod for the Treatment of Ulcerative Colitis Open
View article: High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists Open
The interleukin-6 family cytokine, oncostatin-M (OSM) has been associated with response to tumor necrosis factor-α antagonists (anti-TNFs) in small cohorts of patients with inflammatory bowel disease (IBD). We aimed to evaluate the associa…
View article: P282 High plasma oncostatin-M predicts non-response to tumour necrosis factor-alpha antagonists in inflammatory bowel disease
P282 High plasma oncostatin-M predicts non-response to tumour necrosis factor-alpha antagonists in inflammatory bowel disease Open
Background The interleukin-6 family cytokine, oncostatin-M (OSM) has been associated with a lack of remission to tumor necrosis factor-α antagonists (anti-TNFs) in small cohorts of patients with inflammatory bowel disease (IBD). We aimed t…
View article: Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study
Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study Open
INTRODUCTION: Azathioprine-induced pancreatitis is an idiosyncratic and unpredictable response, occurring in up to 7% of azathioprine-exposed patients with inflammatory bowel disease (IBD). The haplotype HLADQA1-HLADRB1*07:01A>C is strongl…
View article: A12 PRE-TREATMENT HLADQA1-HLADRB1 TESTING FOR THE PREVENTION OF AZATHIOPRINE-INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
A12 PRE-TREATMENT HLADQA1-HLADRB1 TESTING FOR THE PREVENTION OF AZATHIOPRINE-INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY Open
Background Azathioprine (AZA) therapy has a long history of use in IBD. The need to promote its safe use in this population is ensured by governmental health policy requiring IBD patients to fail low cost drugs, such as AZA, prior to appro…
View article: A177 METHOTREXATE FOR THE INDUCTION OF REMISSION IN ULCERATIVE COLITIS
A177 METHOTREXATE FOR THE INDUCTION OF REMISSION IN ULCERATIVE COLITIS Open
Background Obtaining steroid-free remission in Ulcerative Colitis (UC) is a clinically important parameter that can mitigate the development of disease-related complications and lead to improved quality of life. Aims A systematic review to…
View article: A134 A MULTI-CENTRE RANDOMIZED CONTROLLED TRIAL TO COMPARE TWO BOWEL CLEANSING REGIMENS AFTER A COLONOSCOPY WITH INADEQUATE BOWEL PREPARATION
A134 A MULTI-CENTRE RANDOMIZED CONTROLLED TRIAL TO COMPARE TWO BOWEL CLEANSING REGIMENS AFTER A COLONOSCOPY WITH INADEQUATE BOWEL PREPARATION Open
Aims Failed bowel preparation is common during colonoscopy, yet the optimal purgative regimen to use for the next attempt is unknown. The objective of this study was to compare the efficacy, tolerability, and safety of two regimens at supr…
View article: Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews
Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews Open
The Cochrane Inflammatory Bowel Diseases Group presented a symposium at Digestive Diseases Week 2019 entitled “Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews”. This article summa…
View article: Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn’s disease: a systematic review
Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn’s disease: a systematic review Open
Thiopurines are proven agents in the treatment of Crohn’s disease. While pancreatitis is recognised as an adverse event associated with therapy, the effect size and morbidity of thiopurine-induced pancreatitis is not known. The aim of this…
View article: P821 HLADQA1-HLADRB1 pre-emptive screening for azathioprine-induced pancreatitis in inflammatory bowel disease: a preliminary report
P821 HLADQA1-HLADRB1 pre-emptive screening for azathioprine-induced pancreatitis in inflammatory bowel disease: a preliminary report Open
Background Genetic variation in the HLADQA1-HLADRB1*07:01 haplotype is strongly associated with azathioprine (AZA)-induced pancreatitis in inflammatory bowel disease (IBD). We aimed to evaluate the utility of pre-emptive HLA DQA1-HLADRB1*0…
View article: Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews
Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews Open
The Cochrane IBD Group presented a symposium at Digestive Diseases Week 2018 entitled “Alternative and Complementary Approaches for the Treatment of IBD: Evidence from Cochrane Reviews.” This article summarizes the data presented at this s…
View article: A111 LONG-TERM SAFETY AND OUTCOMES OF COLONOSCOPIC BALLOON DILATION FOR STRICTURING CROHN’S DISEASE
A111 LONG-TERM SAFETY AND OUTCOMES OF COLONOSCOPIC BALLOON DILATION FOR STRICTURING CROHN’S DISEASE Open
BACKGROUND: Stricture formation occurs in 18% of Crohn’s disease (CD) patients with long-term disease. Traditionally, surgical therapy has been required to treat the strictures. However, colonoscopic balloon dilation (CBD) has become the s…
View article: A130 SAFETY OF COMBINATION BIOLOGIC AND ANTI-REJECTION THERAPY POST-LIVER TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: LONDON ONTARIO EXPERIENCE
A130 SAFETY OF COMBINATION BIOLOGIC AND ANTI-REJECTION THERAPY POST-LIVER TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: LONDON ONTARIO EXPERIENCE Open
BACKGROUND: Despite anti-rejection immunosuppressive therapies post-liver transplantation (LT), patients with concurrent inflammatory bowel disease (IBD) may have persistent bowel inflammation that requires addition of biologic therapy. AI…
View article: DOP39 Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience
DOP39 Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience Open
Despite anti-rejection immunosuppressive therapies post-liver transplantation (LT), patients with concurrent inflammatory bowel disease (IBD) may have persistent bowel inflammation that requires addition of biologic therapy. The aim of thi…
View article: Systematic review with meta‐analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies
Systematic review with meta‐analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies Open
Summary Background Aminosalicylates are the most frequently prescribed treatment for ulcerative colitis (UC). In the absence of empirical evidence, clinicians are uncertain whether to continue aminosalicylates in patients with UC after esc…
View article: Cannabis for the treatment of Crohn's disease
Cannabis for the treatment of Crohn's disease Open
Background Crohn's disease (CD) is a chronic immune‐mediated condition of transmural inflammation in the gastrointestinal tract, associated with significant morbidity and decreased quality of life. The endocannabinoid system provides a pot…
View article: Cannabis for the treatment of ulcerative colitis
Cannabis for the treatment of ulcerative colitis Open
The effects of cannabis and cannabidiol on UC are uncertain, thus no firm conclusions regarding the efficacy and safety of cannabis or cannabidiol in adults with active UC can be drawn.There is no evidence for cannabis or cannabinoid use f…
View article: Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease
Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease Open
Summary Background Aminosalicylates are the most frequently prescribed drugs for patients with Crohn's disease ( CD ), yet evidence to support their efficacy as induction or maintenance therapy is controversial. Aims To quantify aminosalic…
View article: Low dose naltrexone for induction of remission in Crohn's disease
Low dose naltrexone for induction of remission in Crohn's disease Open
Crohn's disease is a transmural, relapsing inflammatory condition afflicting the digestive tract. Opioid signalling, long known to affect secretion and motility in the gut, has been implicated in the inflammatory cascade of Crohn's disease…
View article: Letter: predicting azathioprine‐associated pancreatitis in <scp>IBD</scp>—phenotype or genotype? Authors' reply
Letter: predicting azathioprine‐associated pancreatitis in <span>IBD</span>—phenotype or genotype? Authors' reply Open
Linked Content This article is linked to Wilson et al and Teich et al papers. To view these articles visit https://doi.org/10.1111/apt.14483 and https://doi.org/10.1111/apt.14545 .
View article: A126 REAL WORLD CLINICAL EFFICACY OF LOW DOSE USTEKINUMAB INDUCTION IN CROHN’S PATIENTS REFRACTORY TO ANTI-TNF THERAPY
A126 REAL WORLD CLINICAL EFFICACY OF LOW DOSE USTEKINUMAB INDUCTION IN CROHN’S PATIENTS REFRACTORY TO ANTI-TNF THERAPY Open
BACKGROUND: Patients with moderate to severe Crohn’s disease refractory or intolerant to steroids, immunomodulators and anti-TNF therapy currently have few options for medical management outside of clinical trials. Ustekinumab, a monoclona…
View article: A145 “REAL WORLD” SAFETY AND EFFECTIVENESS OF VEDOLIZUMAB FOR ULCERATIVE COLITIS: RETROSPECTIVE STUDY FROM A TERTIARY CARE CANADIAN CENTRE
A145 “REAL WORLD” SAFETY AND EFFECTIVENESS OF VEDOLIZUMAB FOR ULCERATIVE COLITIS: RETROSPECTIVE STUDY FROM A TERTIARY CARE CANADIAN CENTRE Open
BACKGROUND: Vedolizumab (VDZ), a humanized monoclonal antibody which targets the α4β7 integrin and prevents homing of lymphocytes to the gut, was approved by Health Canada in 2015 for treatment of moderate to severe ulcerative colitis (UC)…